• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Novartis Ag ADR (NY: NVS )

    97.37 +0.24 (+0.25%)
    Streaming Delayed Price Updated: 2:23 PM EDT, May 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 640,499
    Open 96.97
    Bid (Size) 97.36 (2)
    Ask (Size) 97.37 (1)
    Prev. Close 97.13
    Today's Range 96.72 - 97.49
    52wk Range 92.19 - 108.78
    Shares Outstanding N/A
    Dividend Yield 3.56%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib
    MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute myeloid leukemia. FDA alerted. Novartis acquisition proceeds... 
    Via Benzinga
    Exposures Product Safety
    AbbVie Outlook: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales
    The company is projected to bring in increasing sales through at least 2029. 
    Via Investor's Business Daily

    Performance

    YTD
    -3.59%
    -3.59%
    1 Month
    +1.56%
    +1.56%
    3 Month
    -9.63%
    -9.63%
    6 Month
    +4.05%
    +4.05%
    1 Year
    -5.04%
    -5.04%

    More News

    Read More
    Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates
    Via Talk Markets
    What's Going On With Pfizer Stock On Thursday?
    Via Benzinga
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    Novartis Extends Three-Day Stock Sprint With First-Quarter Beat And Raise
    Via Investor's Business Daily
    Looking At Novartis's Recent Unusual Options Activity
    Via Benzinga
    Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
    Via Investor's Business Daily
    Why Novartis Stock Topped the Market on Tuesday
    Via The Motley Fool
    FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
    Via Benzinga
    Exposures Product Safety
    NVS Stock Earnings: Novartis Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Novartis Ag (NVS) Q1 2024 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Stocks Rally On Weaker PMI Data, Tech Earnings Optimism, Dollar Falls: What's Driving Markets Tuesday?
    Via Benzinga
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook
    Via Benzinga
    Wall Street Set To Open Higher As Tesla Kicks Off 'Magnificent 7' Earnings: Why This Analyst Thinks Market Weakness Is A 'Healthy Pullback'
    Via Benzinga
    Topics Bonds
    Exposures Debt Markets
    Top Analyst Reports For Novartis, American Express & ConocoPhillips
    Via Talk Markets
    The Bad News Heading Into AbbVie's First-Quarter Earnings Report
    Via Investor's Business Daily
    FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
    Via Benzinga
    Exposures Product Safety
    Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years
    Via Benzinga
    2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
    Via The Motley Fool
    Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
    Via Benzinga
    Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
    Via Benzinga
    Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%.
    Via The Motley Fool
    Topics ETFs
    Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
    Via Benzinga
    Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
    Via Investor's Business Daily
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.